2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Radiation Therapy, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Hemoglobinopathies, Infectious Diseases, Viral, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5764 Real-world response to teclistamab plus daratumumab by prior anti-CD38 exposure in multiple myeloma

Robert Scheel, MD, Rahma Warsame, MD2, Suzanne Hayman, MD3, Angela Dispenzieri, MD4, Morie Gertz, MD5, Francis Buadi, MD6, Prashant Kapoor, MD7, David Dingli, MD, PhD8, Nadine Abdallah I, MD9, Wilson Gonsalves, MD10, Taxiarchis Kourelis, MD11, Saurabh Zanwar, MBBS, MD12, S. Vincent Rajkumar, MD13, Shaji Kumar, MD14, Moritz Binder, MD, MPH15, Yi Lin Jr, MD, PhD16, Amie Fonder, PA-C17, Yi Hwa, DNP18, Miriam Hobbs, CNP19, Joselle M Cook, M.D.20
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States

BACKGROUND

Teclistamab is a B-cell maturation antigen-directed bispecific antibody, and daratumumab targets CD38. In MajesTEC-3, teclistamab plus daratumumab (Tec-Dara) in 1-3 prior lines yielded an unprecedented progression-free survival benefit in relapsed/refractory multiple myeloma (MM), and Tec-Dara was FDA approved in the second-line setting on March 5, 2026. Daratumumab may augment BCMA-directed T-cell redirection by depleting immunosuppressive CD38+ immune cells and enhancing endogenous T-cell function. However, although daratumumab-exposed patients were allowed in MajesTEC-3, only 5.3% of enrolled patients had prior anti-CD38 exposure, and daratumumab-refractory patients were excluded. With daratumumab a cornerstone of frontline quadruplet therapy, many patients considered for Tec-Dara in practice will have prior CD38 exposure or CD38-refractory disease. We evaluated real-world response rate, depth, and kinetics after Tec-Dara by prior anti-CD38 exposure and refractoriness.

METHODS

We retrospectively analyzed patients with MM treated with Tec-Dara at Mayo Clinic; data cutoff was July 27, 2026. Patients with concurrent AL amyloidosis were included when Tec-Dara was given for MM. Cohorts were all patients, prior anti-CD38-exposed (exposed), and prior anti-CD38-unexposed (unexposed). High-risk cytogenetic abnormalities were defined according to the 2025 IMS/IMWG consensus. Best response was the deepest response documented from Tec-Dara initiation through last disease assessment. Overall response rate (ORR) was partial response (PR) or better; depth endpoints were very good partial response (VGPR) or better and near complete response (nCR). nCR required suppressed serum free light chains with mass spectrometry <0.02 mg/dL. Complete response was not assigned because post-treatment marrow biopsies were generally unavailable. Response rates used all-treated denominators with exact binomial 95% confidence intervals (CIs). Analyses were descriptive. The study was approved by the institutional review board and conducted per the Declaration of Helsinki.

RESULTS

Twenty-seven patients received Tec-Dara: 66.7% (n=18) had prior anti-CD38 exposure, 59.3% (n=16) had CD38-refractory disease, and 33.3% (n=9) were anti-CD38 unexposed. 66.7% (n=18) would have been ineligible for MajesTEC-3 because of CD38-refractory disease and/or >3 prior lines of therapy. Median age was 75 years (range, 42-83); 55.6% (n=15) had prior ASCT. Median prior lines was 2 (range, 1-12). Anti-CD38-exposed patients were more heavily pretreated (median 3 vs 1 prior lines) and more frequently harbored high-risk cytogenetics (50.0% vs 12.5%). Among exposed, 94.4% (17/18) had received daratumumab and 88.9% (16/18) were CD38-refractory. Median follow-up was 57 days (range, 4-159), shorter in exposed than unexposed patients (56.5 vs 84 days). Best response was PR in 4, VGPR in 6, nCR in 11, stable disease in 1, and progressive disease in 5. ORR was 77.8% (21/27) overall (95% CI, 57.7-91.4), 77.8% (14/18) in CD38-exposed patients (95% CI, 52.4-93.6), and 77.8% (7/9) among anti-CD38-unexposed patients (95% CI, 40.0-97.2). Among CD38-refractory patients, ORR was 81.2% (13/16; 95% CI, 54.4-96.0). VGPR or better occurred in 63.0% overall (95% CI, 42.4-80.6), 55.6% exposed (95% CI, 30.8-78.5), and 77.8% unexposed (95% CI, 40.0-97.2). nCR occurred in 40.7% overall (95% CI, 22.4-61.2), 38.9% exposed (95% CI, 17.3-64.3), and 44.4% unexposed (95% CI, 13.7-78.8). Among responders, median time to first response was 28 days (range, 5-37) overall, 20.5 days (5-34) exposed, and 29 days (7-37) unexposed; median time to best response was 29 days (range, 14-149), 28 days (14-57), and 37 days (28-149), respectively.

CONCLUSIONS

Tec-Dara demonstrated robust and rapid clinical activity in patients with CD38-refractory MM, with responses observed despite prior resistance to anti-CD38 antibody therapy. Notably, two-thirds of patients in our cohort would have been ineligible for MajesTEC-3 because of CD38-refractory disease and/or >3 prior lines of therapy. These findings suggest that the immunomodulatory effects of daratumumab may augment BCMA-directed T-cell redirection despite prior CD38-refractory disease and support further evaluation of Tec-Dara in patients with prior CD38-refractory disease.

Robert Scheel, MD: No relevant conflicts of interest to declare.